Molecular pathogenesis of borderline and invasive ovarian tumors

Journal of B.U.ON.

Volumn 14, Issue 1, 2009, Pages 7-18

  Stanojevic, Z ^a   Djordjevic, B ^a   Pajovic, S B ^b   Zivanov Curlis, J ^b   Najman, Stevo ^b  

^a Clinical Center   (Serbia)

^b Faculty of Medicine   (Serbia)

Author keywords

Borderline tumors; Molecular pathogenesis; Ovarian cancer

Indexed keywords

ESTROGEN; K RAS PROTEIN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

CANCER INVASION; CANCER PREVENTION; CARCINOGENESIS; DNA DAMAGE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC DAMAGE; HETEROZYGOSITY LOSS; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; OVARY CANCER; OVARY TUMOR; OXIDATIVE STRESS; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 64249153113     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ (Ed): Blaustein's Pathology of the Female Genital Tract (5th edn). New York: Springer-Verlag, 2002, pp 791-904.
2. Scully RE. World Health Organization International Histological Classification of Tumors (2nd edn). New York (NY): Springer, 1999.
3. Scully RE. International Histological Classification of Tumors: histological typing of ovarian tumors. Geneva: WHO, 1999.
4. Shih IM, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005; 11: 7273-7279.
5. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001; 22: 255-288.
6. Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revising old hypothesis. Mol Cell Endocrinol 2006; 247: 4-21.
7. Davies BR, Finnigan DS, Smith SK, Ponder BA. Administration of gonadotropins stimulates proliferation of normal mouse ovarian surface epithelium. Gynecol Endocrinol 1999; 13: 75-81.
8. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001; 61: 6768-6776.
9. Choi JH, Choi KC, Auersperg N, Leung PC. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res 2006; 66: 3912-3920.
10. Siemens CH, Auersperg N. Serial propagation on human ovarian surface epithelium in tissue culture. J Cell Physiol 1988; 134: 347-356.
11. Dabrow MB, Francesco MR, McBrearty FX, Caradonna S. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol 1998; 71: 29-37.
12. Takahashi H, Behbakht K, McGovern PE et al. Mutation analysis of BRCA1 gene in ovarian cancer. Cancer Res 1995; 55: 2998-3002.
13. Berchuck A, Heron K, Carney ME et al. Frequency of germ-line and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998; 4: 2433-2437.
14. Lancaster JM, Wooster R, Mangion J et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996; 13: 1-5.
15. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
16. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-646.
17. Campbell IG, Morland S, Hitchcock A et al. Endometriosis and the relationship with ovarian cancer. In: Sharp F, Blackett T, Derek J, Bast R (Eds): Ovarian Cancer, vol. 5. Oxford: ISIS Medical Media Ltd, 1998, pp 159-170.
18. Obata K, Morland SJ, Watson RH et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998; 58: 2059-2097.
19. Bell DA, Scully RE. Early de novo ovarian carcinoma. Cancer 1994; 73: 1859-1864.
20. Schorge J, Mok SC. Understanding the pathogenesis of primary peritoneal carcinoma: involvement of the BRCA1 and p53 genes. Hum Pathol 1999; 30: 115-116.
21. Mok SC, Lu KH, Ng S et al. Molecular pathogenesis of borderline and invasive ovarian tumors. In: Jacobs JI, Shepher HJ, Oram HD et al (Eds): Ovarian cancer. (2nd edn). Oxford: University Press, 2002, pp 97-103.
22. Jacobs IJ, Kohler MF, Wiseman RW et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992; 84: 1793-1798.
23. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk. Collaborative analysis of twelve US case-control studies: IV. The pathogenesis of epithelial ovarian cancer. Am J Epidemiol 1992; 136: 1212-1220.
24. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19: 3-10.
25. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998; 90: 1774-1786.
26. Ames BN, Gold LS. Too many rodent carcinogens: Mitogenesis increases mutagenesis. Science 1990; 249: 970-971.
27. Rodriguez GC, Walmer DK, Cline M et al. Effect of progestin on the ovarian epithelium of macaques: Cancer prevention through apoptosis? J Soc Gynecol Invest 1998; 5: 271-276.
28. Bauknecht T, Kiechle M, Bauer G, Siebers JW. Characterization of growth factors in human ovarian carcinomas. Cancer Res 1986; 46: 2614-2618.
29. Kommoss F, Wintzer HO, Von Kleist S et al. In situ distribution of transforming growth factor-α in normal human tissues and in malignant tumours of the ovary. J Pathol 1990; 162: 223-230.
30. Morishige K, Kurachi H, Amemiya K et al. Evidence for the involvement of transforming growth factor-α and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancer in vitro. Cancer Res 1991; 51: 5322-5328.
31. Pinkas-Kramarski R, Shelly M, Guarino BC et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 1998; 18: 6090-6101.
32. Berchuck A, Kamel A, Whitaker R et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087-4091.
33. Pegram MD, Finn RS, Arzoo K et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15: 537-547.
34. Yee D, Morales FR, Hamilton TC, Von Hoff DD. Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res 1991; 51: 5107-5112.
35. Conover CA, Hartmann LC, Bradley S et al. Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res 1998; 238: 439-449.
36. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-1489.
37. Lu L, Katsaros D, Wiley A et al. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-α expression to disease progression in epithelial ovarian cancer. Clin Cancer Res 2006; 12: 1208-1214.
38. Di Blasio AM, Cremononesi L, Vigano P et al. Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms. Am J Obstet Gynecol 1993; 169: 1517-1523.
39. Ramakrishnan S, Xu FJ, Brandt SJ et al. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest 1989; 83: 921-926.
40. Kacinski BM, Stanley ER, Carter D et al. Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. Int J Radiat Oncol Biol Phys 1989; 17: 159-164.
41. Kacinski BM, Carter D, Mittal K et al. Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Am J Pathol 1990; 137: 135-147.
42. Wu S, Rodabaugh K, Martinez-Maza O et al. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6 and tumor necrosis factor-α. Am J Obstet Gynecol 1992; 166: 997-1007.
43. Wu S, Boyer CM, Whitaker RS et al. Tumor necrosis factor-α as an autocrine and paracrine growth factor for ovarian cancer: Monokine induction of tumor cell proliferation and tumor necrosis factor-α expression. Cancer Res 1993; 53: 1939-1944.
44. Fang X, Gibson S, Flowers M et al. Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. J Biol Chem 1997; 272: 13683-13689.
45. Mills GB, May C, Hill M et al. Ascites fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 1990; 86: 851-855.
46. Facchini LM, Penn LZ. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J 1998; 12: 633-651.
47. Tashiro H, Niyazaki K, Okamura H et al. c-myc overexpression in human primary ovarian tumors: Its relevance to tumor progression. Int J Cancer 1992; 50: 828-833.
48. Pajovic S, Pejic S, Kasapovic J, Radojcic M, Borojevic N, Radosevic-Jelic Lj. Role of superoxide dismutase in individualization of breast cancer radiation therapy protocols. Arch Oncol 2003; 11: 191-192.
49. Kanazir DT, Pajovic SB, Radojcic MB. Molecular mechanism of stress induced cardiovascular disease. Serbian Academy of Sciences and Art. Monographs Vol. DCLV, 2004, 1-94.
50. Pajovic SB, Kasapovic J, Pejic S, Stankovic J, Borojevic N, Radosevic-Jelic Lj. Superoxide dismutase profile in circulation of breast cancer patients as a predictive assay in radiotherapy. Jugosl Physiol Pharmacol Acta 2004; 40: 151-158.
51. Breimer LH. Molecular mechanisms of oxygen radical carcinogenesis and mutagenesis: the role of DNA base damage. Mol Carcinogen 1990; 3: 188-197.
52. Feig DI, Reid TM, Loeb LA. Reactive oxygen species in tumorigenesis. Cancer Res 1994; 54: 1890s-1894s.
53. Floyd RA. 8-Hydroxy-2′-deoxyguanosine in carcinogenesis. Carcinogenesis 1990; 11: 1447-1450.
54. Rice-Evans C, Burdon R. Free radical - lipid interactions and their pathological consequences. Prog Lipid Res 1993; 32: 71-110.
55. White AA, Crawford KM, Patt CS, Lad PJ. Activation of soluble guanylate cylase from rat lung by incubation or by hydrogen peroxide. J Biol Chem 1976; 251: 7304-7312.
56. 2+ sequestration by the plasma membrane fraction from rat liver. FEBS Lett 1983; 163: 136-139.
57. Kerr LD, Inoue J, Verm IM. Signal transduction: the nuclear target. Curr Opin Cell Biol 1992; 4: 496-501.
58. Davies AKJA. Intracellular proteolytic systems may function as secondary antioxidants defenses: a hypothesis. J Free Radic Biol Med 1986; 9: 155-173.
59. Nelson RL. Dietary iron and colorectal cancer risk. Free Radic Biol Med 1992; 12: 161-168.
60. Pejic S, Todorovic A, Stojiljkovic V et al. Superoxide dismutase and lipid hydroperoxides in blood and endometrial tissue of patients with benign, hyperplastic and malignant endometrium. An Acad Bras Cienc 2008; 80: 515-522.
61. Pejic S, Kasapovic J, Todorovic A, Stojiljkovic V, Pajovic SB. Lipid peroxidation and antioxidant status in blood of patients with uterine myoma, endometrial polypus, hyperplastic and malignant endometrium. Biol Res 2006; 39: 619-629.
62. Lu KH, Bell DA, Welch WR et al. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 1998; 58: 2328-2330.
63. Mok SC, Tsao SW, Knapp RC et al. Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 1992; 52: 5119-5122.
64. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
65. Mok SC, Bell DA, Knapp RC et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993; 53: 1489-1492.
66. Singer G, Kurman RJ, Chang HW, Cho SKR, Shih IM. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002; 160: 1223-1228.
67. Singer G, Oldt R III, Cohen Y et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95: 484-686.
68. Milner BJ, Allan LA, Eccles DM et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53: 2128-2132.
69. Singer G, Stohr R, Cope L et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immuno-histochemical correlation. Am J Surg Pathol 2005; 29: 218-224.
70. Wertheim I, Muto MG, Welch WR et al. p53 gene mutations in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994; 86: 1549-1551.
71. Hsu CY, Bristow R, Cha M et al. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 2004; 10: 6432-6436.
72. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-465.
73. Satyamoorthy K, Li G, Gerrero MR et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003; 63: 756-759.
74. Pohl G, Ho CL, Kurman RJ et al. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 2005; 65: 1994-2000.
75. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004; 23: 200-205.
76. Edelson MI, Lau CC, Colitti CV et al. A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors. Oncogene 1998; 16: 197-202.
77. Tangir J, Loughridge NS, Berkowitz RS et al. Frequent microsatellite instability in epithelial borderline ovarian tumors. Cancer Res 1996; 56: 2501-2505.
78. Colitti CV, Rodabaugh KJ, Welch WR et al. A novel 4 cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinomas. Oncogene 1998; 16: 555-559.
79. Edelson MI, Scherer SW, Tsui LC et al. Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas. Oncogene 1997; 14: 2979-2984.
80. Huang LW, Garrett AP, Schorge JO et al. Detailed mapping of chromosome 6q in papillary serous carcinoma of the peritoneum compared with high grade late stage invasive serous epithelial ovarian carcinomas. Proc Am Assoc Cancer Res 1999; 40: 543-544.
81. Lu KH, Weitzel JN, Srilatha K et al. A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade non-mucinous epithelial ovarian carcinomas. Cancer Res 1997; 57: 387-390.
82. Wertheim I, Tangir J, Muto MG et al. Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors. Oncogene 1996; 12: 2147-2153.
83. Tangir J, Muto MG, Berkowitz RS et al. A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer. Oncogene 1996; 12: 735-740.
84. Staebler A, Heselmeyer-Haddad K, Bell K et al. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalance by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol 2002; 33: 47-59.
85. Meinhold-Heerlein I, Bauerschlag D, Hilpert F et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005; 24: 1053-1065.
86. Krishnamurti U, Sasatomi E, Swalsky PA, Jones MW, Finkelstein SD. Microdissection-based mutational genotyping of serous borderline tumors of the ovary. Int J Gynecol Pathol 2005; 24: 56-61.
87. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005; 96: 684-694.
88. Mok SC, Chan WY, Wong KK et al. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 1996; 12: 1895-1901.
89. Mok SC, Chan WY, Wong KK et al. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998; 16: 2381-2387.
90. Tanner B, Kreutz E, Weikel W et al. Prognostic significance of c-erb-2 mRNA in ovarian carcinoma. Gynecol Oncol 1996; 62: 268-277.
91. Kaghan M, Bonnet H, Yang A et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-819.